Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise

Executive Summary

Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category

You may also be interested in...



Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead

Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta

Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead

Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta

Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review

Inhaled insulin manufacturers are emphasizing smaller devices and easier dosing of their products following the review of Pfizer/Sanofi-Aventis' Exubera by FDA's Endocrinologic & Metabolic Drugs Advisory Committee

UsernamePublicRestriction

Register

PS046707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel